Nupeak Therapeutics Inc.
Clayton, MO
- UEI
- KLCRCAQBG417
- CAGE
- 6TUS1
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 14 Brentmoor Park, Clayton, MO 63105, USA
- Website
- nupeak-therapeutics.com
- Founded
- 2009
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The Washington University | W81XWH2010603 | -$140,000 | |
| The Washington University | W81XWH2210281 | $199,128 | |
| The Washington University | W81XWH2210281 | $551,009 | |
| The Washington University | W81XWH2010603 | $545,743 |
Latest 4 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Thetis Pharmaceuticals LLC | Deep River, CT | — |
| Parion Sciences, Inc. | Durham, NC | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| 3 Point Bio LLC | Boxford, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Kevirx Inc. | Charlottesville, VA | — |
| Max Biopharma, Inc. | Santa Monica, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Nupeak Therapeutics Inc. is a for-profit biotechnology company that provides drug development and contract research services to the federal government. According to the vendor information, Nupeak Therapeutics is focused on developing small-molecule kinase inhibitors for airway disease.
Through past federal grants, Nupeak Therapeutics has provided preclinical and clinical research services related to the development of a new inhaled compound called NUP-4A for the treatment of airway diseases like asthma and COPD. As a subawardee under grants from the National Institutes of Health, Nupeak has conducted pharmacology, toxicology and formulation studies of NUP-4A using contract research organizations. Specific services include non-GLP maximum tolerated dose studies, Good Laboratory Practice toxicology assessments, inhaled formulation development, and collecting data for FDA Investigational New Drug applications. Nupeak has also overseen chemistry, manufacturing and controls activities like developing synthetic processes, formulating drugs, and manufacturing compounds. As the industry partner, Nupeak coordinates research activities between academia, contract organizations, and consultants while managing federal grants focused on translating early stage compounds into novel inhaled therapies.
Quick answers
Is Nupeak Therapeutics Inc. registered in SAM.gov?
Yes. Nupeak Therapeutics Inc.'s SAM.gov registration is active through February 11, 2027.
What is Nupeak Therapeutics Inc.'s most recent federal award?
Nupeak Therapeutics Inc.'s most recent federal grant award is A new small-molecule kinase inhibitor for airway disease - title a new small-molecule kinase inhibitor for airway… (R42HL149523), from National Heart Lung and Blood Institute (NIH), on August 7, 2019.
On GovTribe
See Nupeak Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors